COMPANY NEWS
5
SERVICE CENTRE – LOCATIONS – TECHNOLOGY & PRODUCT DEVELOPMENT –
NEWS AND INFORMATION
n recent years, the SCHERDEL-
Group has been able to increasingly
extend its product portfolio. The trend is
definitely moving towards intricate as-
semblies developed in partnership with
clients and consisting of various individ-
ual parts, such as springs, shaped wire
components, stamped components and
tubes. These parts are either assem-
bled by the Group’s assembly teams to
create fully functional components or al-
ternatively put together “on site” at the
customer’s production facilities using
plant systems developed by
SCHERDEL. Regardless of the method
being employed, cleanliness during the
production of various individual parts
plays an increasingly vital role. It is a
major issue particularly in the medical
engineering sector where people’s lives
depend on the perfect condition and re-
liable operation of the supplied assem-
blies. The SCHERDEL subsidiary
Spires 2000 in the French city of Beau-
vais specialises in the production of ro-
tary shaft seal springs for the automo-
tive industry and springs for medical
applications. Development and commis-
sioning of a clean room production fa-
cility at the French SCHERDEL plant
ensure it is now better equipped to
meet the medical industry’s growing de-
mand for component parts.
When producing springs for the phar-
maceutical sector, Spires 2000 must
ensure every part is finished to the
highest levels of precision and in the
cleanest environment possible to ex-
clude any potential bacterial contamina-
tion. A major difference to the automo-
tive industry is that the pharmaceutical
sector requires much longer lead times
for the acceptance and validation of
manufacturing processes until final ap-
proval is received. The reason for this
is quite simply that the processes can-
not be altered once they have been ap-
proved and examined. The industry al-
so pays particular attention to risk
analysis when assessing the process-
es. The central question here is always
whether there is a risk for users or pa-
tients and how, if necessary, it can be
minimised. The past two years in Beau-
vais have been spent ensuring mem-
bers of staff there are qualified to an
appropriate level of process safety ex-
pertise and the organisational struc-
tures are in place for clean room pro-
duction to ISO 7. The standard ISO 7
complies with a high degree of cleanli-
ness based on the amount of micro-
scopic particles found per cubic metre
of air within the standard classification
of clean rooms to ISO 14644. Work at
the SCHERDEL subsidiary has now
moved into the final phase of the ap-
proval process for the new clean room
production facility, which is located in a
separate building. But it does not stop
there – SCHERDEL is currently looking
at all its customers worldwide to assess
whether the increasing importance
placed on cleanliness will also become
more essential for the requirement pro-
files of their products. After evaluating
the ongoing analyses, it is reasonable
to assume that the acquisition of clean
room facilities will be a key feature of
future investment plans at the Group’s
other manufacturing locations.
(dk)
I
Increasing importance
of cleanliness
SCHERDEL invests in clean room production
The new clean room at Spires 2000
in Beauvais is about to be commis-
sioned.
Contact
Dr. Peter Taubmann
“Chief Cleanliness Officer”
of the SCHERDELGroup
Tel. +49 9231 603-6460
peter.taubmann@
scherdel.de
Patrick Foucart
Manager of Plant Scherdel
Herckelbout-Dawson
Tel.: +33 344 10-5229
Dipl. Ing (FH)
Bernhard Walter
Managing Director of
Medical Engineering
Tel.: +49 9231 603 6426
bernhard.walter@
scherdel.de
Ingo Maurach
Medical Engineering Sales
Tel.: +49 9231 603 427
